Raphael K. Yeboah

Mr. Raphael K. Yeboah

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
AOAbdul-Halim Osman
Abdul-Halim Osman
Fleischer C. N. KoteyFleischer C. N. Kotey
Fleischer C. N. Kotey
AOAlex Odoom
Alex Odoom
SDSamuel Darkwah
Samuel Darkwah
RYRaphael K. Yeboah
Raphael K. Yeboah
EDEric Donkor
Eric Donkor
The growing threat of antibiotic resistance is a significant global health challenge that has intensified in recent years. The burden of antibiotic resistance on public health is augmented due to its multifaceted nature, as well as the slow-paced and limited development of new antibiotics. The threat posed by resistance is now existential in phage therapy, which had long been touted as a promising replacement for antibiotics. Consequently, it is imperative to explore the potential of combination therapies involving antibiotics and phages as a feasible alternative for treating infections with multidrug-resistant bacteria. Although either bacteriophage or antibiotics can potentially treat bacterial infections, they are each fraught with resistance. Combination therapies, however, yielded positive outcomes in most cases; nonetheless, a few combinations did not show any benefit. Combination therapies comprising the synergistic activity of phages and antibiotics and combinations of phages with other treatments such as probiotics hold promise in the treatment of drug-resistant bacterial infections.